The present invention relates to novel liquid pharmaceutical compositions ofadalimumab, whichinclude adalimumab or a biosimilar thereof, an acetate buffering agent/systemsuch as sodiumacetate/acetic acid, and a sugar stabiliser such as trehalose. Such acombination of componentsfurnishes formulations having a stability (e.g. on storage and when exposed tostress) which iscomparable to or an improvement upon those known in the art, and with feweringredients. Suchadvances will help adalimumab treatments to become more widely available atlower cost, andprolong the viability of pre-loaded delivery devices (e.g. pre-filledsyringes) to reduceunnecessary waste of the drug.
